Amgen: Humira Interchangeability ‘A Nice To Have, Not A Need To Have’
‘Many’ Biosimilars Sponsors ‘Struggled’ With Key Issue Of Continuous Supply
Executive Summary
Amgen management spoke at length about biosimilars during the company’s two-and-a-half-hour-long business review meeting, with the launch of its Amjevita (adalimumab-atto) biosimilar now less than a year away.
You may also be interested in...
Amgen’s Biosimilars Business Dips As Key Contributors Face Fresh Competition
Two of Amgen’s flagship biosimilar products saw a notable drop in sales in Q1 in the face of increased competition, but impending launches are expected to put the unit back on track.
Amgen’s Stelara Biosimilar Produces Positive Phase III Results
Amgen has reported positive preliminary results from a Phase III study for its ABP 654 proposed ustekinumab biosimilar rival to Stelara, for which the firm also intends to pursue an interchangeability designation.
Coherus Has $2.2bn Revenue Ambition By 2026 – But Humira Is Key
During the company’s landmark first annual analyst day, Coherus BioSciences management spoke at length about its ambitions for Coherus to generate north of $2bn in revenues by 2026, with much riding on how it fares in the impending biosimilar Humira market.